ES2163017T3 - Compuestos de bencilaminopiperidina sustituidos. - Google Patents
Compuestos de bencilaminopiperidina sustituidos.Info
- Publication number
- ES2163017T3 ES2163017T3 ES96914375T ES96914375T ES2163017T3 ES 2163017 T3 ES2163017 T3 ES 2163017T3 ES 96914375 T ES96914375 T ES 96914375T ES 96914375 T ES96914375 T ES 96914375T ES 2163017 T3 ES2163017 T3 ES 2163017T3
- Authority
- ES
- Spain
- Prior art keywords
- halo
- rent
- alcoxyl
- snc
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- -1 HYDROXYL GROUP Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 150000001721 carbon Chemical class 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- KHUXNRRPPZOJPT-UHFFFAOYSA-N phenoxy radical Chemical class O=C1C=C[CH]C=C1 KHUXNRRPPZOJPT-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
ESTA INVENCION PROPORCIONA UN COMPUESTO DE LA FORMULA (I) Y SUS SALES FARMACEUTICAMENTE ACEPTABLES, DONDE R ES HALO C SUB,1 C 8 ALQUILO, HALO C 2 - C 8 ALQUENILO, HALO C 2 - C 8 ALQUINILO O HALO C 1 - C 8 ALQUILO SUSTITUIDO POR UN GRUPO HIDROXILO O C 1 - C 8 AL COXILO; R 1 ES HIDROGENO, HALO O C 1 - C 6 ALCOXILO; O R Y R 1 , JUNTO CON LOS DOS ATOMOS DE CARBONO COMP ARTIDOS POR EL ANILLO DE BENCENO Y R Y R 1 , COMPLETAN UN C 4 C 6 ALQUILO FUSIONADO DONDE UN ATOMO DE CARBONO ES REEMPLAZADO OPCIONALMENTE POR OXIGENO Y DONDE UNO O DOS DE LOS ATOMOS DE CARBONO SON SUSTITUIDOS OPCIONALMENTE POR HASTA CINCO SUSTITUYENTES SELECCIONADOS DE HALO, C 1 - C 6 ALQUILO Y HALO C 1 - C 6 ALQUILO; X ES C 1 - C SUB,6 ALCOXILO, HALO C 1 - C 6 ALCOXILO, FENOXILO O HALO; Y AR ES FENILO OPCIONALMENTE SUSTITUIDO POR HALO. ESTOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE TRASTORNOS GASTROINTESTINALES, DEL SISTEMA NERVIOSO CENTRAL (SNC), UNA ENFERMEDAD INFLAMATORIA, VOMITOS, INCONTINENCIA URINARIAS, DOLOR, MIGRAÑA,QUEMADURAS SOLARES, ENFERMEDADES, TRASTORNOS Y SITUACIONES ADVERSAS CAUSADAS POR HELICOBACTER PYLORI, O TRASTORNOS DE LA ANGIOGENESIS, ESPECIALMENTE DEL SNC, EN MAMIFEROS, ESPECIALMENTE SERES HUMANOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB9500683 | 1995-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2163017T3 true ES2163017T3 (es) | 2002-01-16 |
Family
ID=11004362
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES01108350T Expired - Lifetime ES2211684T3 (es) | 1995-08-24 | 1996-06-10 | Componentes de bencilaminopiperidina sustituidos. |
ES96914375T Expired - Lifetime ES2163017T3 (es) | 1995-08-24 | 1996-06-10 | Compuestos de bencilaminopiperidina sustituidos. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES01108350T Expired - Lifetime ES2211684T3 (es) | 1995-08-24 | 1996-06-10 | Componentes de bencilaminopiperidina sustituidos. |
Country Status (42)
Country | Link |
---|---|
US (1) | US6506775B1 (es) |
EP (2) | EP0861235B1 (es) |
JP (1) | JP3084069B2 (es) |
KR (1) | KR100288673B1 (es) |
CN (1) | CN1153764C (es) |
AP (1) | AP643A (es) |
AR (1) | AR006305A1 (es) |
AT (2) | ATE208377T1 (es) |
AU (1) | AU702698B2 (es) |
BG (1) | BG64126B1 (es) |
BR (1) | BR9609989A (es) |
CA (1) | CA2227814C (es) |
CO (1) | CO4480738A1 (es) |
CZ (1) | CZ297543B6 (es) |
DE (2) | DE69631390T2 (es) |
DK (2) | DK1114817T3 (es) |
DZ (1) | DZ2086A1 (es) |
ES (2) | ES2211684T3 (es) |
HK (1) | HK1014935A1 (es) |
HR (1) | HRP960386B1 (es) |
HU (1) | HU225480B1 (es) |
IL (1) | IL119078A (es) |
IS (1) | IS1947B (es) |
MA (1) | MA23961A1 (es) |
MX (1) | MX9801467A (es) |
MY (1) | MY114800A (es) |
NO (1) | NO310720B1 (es) |
NZ (1) | NZ308207A (es) |
OA (1) | OA10666A (es) |
PE (2) | PE20010700A1 (es) |
PL (1) | PL186773B1 (es) |
PT (2) | PT861235E (es) |
RO (1) | RO119299B1 (es) |
RU (1) | RU2152930C2 (es) |
SI (2) | SI0861235T1 (es) |
SK (1) | SK282925B6 (es) |
TN (1) | TNSN96107A1 (es) |
TR (1) | TR199800300T1 (es) |
TW (1) | TW340842B (es) |
UA (1) | UA48981C2 (es) |
WO (1) | WO1997008144A1 (es) |
YU (1) | YU49122B (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX9706196A (es) * | 1996-08-14 | 1998-02-28 | Pfizer | Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p. |
TW426667B (en) * | 1997-11-19 | 2001-03-21 | Pfizer | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists |
US6777428B1 (en) | 1999-02-10 | 2004-08-17 | Eli Lilly And Company | 5-HT1f agonist |
EP1175417B1 (en) * | 1999-05-06 | 2004-01-07 | Pfizer Products Inc. | Substituted benzolactam compounds |
RS49964B (sr) | 1999-05-17 | 2008-09-29 | Pfizer Products Inc., | Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli |
WO2000071538A2 (en) * | 1999-05-21 | 2000-11-30 | Pfizer Products Inc. | 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives |
JP2001172178A (ja) * | 1999-10-25 | 2001-06-26 | Pfizer Prod Inc | 偏頭痛治療用のnk−1レセプターアンタゴニスト及びエレトリプタン |
US20020049211A1 (en) * | 2000-09-06 | 2002-04-25 | Sobolov-Jaynes Susan Beth | Combination treatment for depression and anxiety |
EP1192952A3 (en) * | 2000-09-28 | 2003-03-26 | Pfizer Products Inc. | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist |
US6911544B2 (en) | 2002-10-23 | 2005-06-28 | Pfizer Inc. | Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine |
WO2004094380A1 (en) | 2003-04-18 | 2004-11-04 | Eli Lilly And Company | (piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists |
CA2566920A1 (en) * | 2004-05-21 | 2005-12-01 | Pfizer Products Inc. | Metabolites of (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine |
US7541357B2 (en) | 2004-07-15 | 2009-06-02 | Amr Technology, Inc. | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
GEP20125566B (en) | 2005-07-15 | 2012-07-10 | Amr Technology Inc | Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
AU2006297443B2 (en) | 2005-09-29 | 2010-08-12 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
CA2664113C (en) | 2006-09-22 | 2013-05-28 | Merck & Co., Inc. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
JP4611444B2 (ja) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としてのアミド置換インダゾール |
CA2682727C (en) | 2007-04-02 | 2016-03-22 | Banyu Pharmaceutical Co., Ltd. | Indoledione derivative |
EP3103791B1 (en) | 2007-06-27 | 2018-01-31 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
US8598184B2 (en) | 2008-03-03 | 2013-12-03 | Tiger Pharmatech | Protein kinase inhibitors |
US7951822B2 (en) | 2008-03-31 | 2011-05-31 | Kowa Company, Ltd. | 1,3-dihydroisobenzofuran derivatives |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
PE20120373A1 (es) | 2009-05-12 | 2012-05-17 | Albany Molecular Res Inc | 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina |
WO2010132487A1 (en) | 2009-05-12 | 2010-11-18 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF |
CN102458123A (zh) | 2009-05-12 | 2012-05-16 | 阿尔巴尼分子研究公司 | 芳基、杂芳基和杂环取代的四氢异喹啉及其用途 |
JP5099731B1 (ja) | 2009-10-14 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | p53活性を増大する置換ピペリジン及びその使用 |
EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
US8518907B2 (en) | 2010-08-02 | 2013-08-27 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
DK2606134T3 (da) | 2010-08-17 | 2019-07-22 | Sirna Therapeutics Inc | RNA-Interferens-formidlet inhibering af hepatitis-B-virus (HBV)-genekspression ved hjælp af kort interfererende nukleinsyre (siNA) |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
US20140045847A1 (en) | 2011-04-21 | 2014-02-13 | Piramal Enterprises Limited | Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
EP3358013B1 (en) | 2012-05-02 | 2020-06-24 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
RU2660429C2 (ru) | 2012-09-28 | 2018-07-06 | Мерк Шарп И Доум Корп. | Новые соединения, которые являются ингибиторами erk |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神***病を処置するための方法および組成物 |
AU2013352568B2 (en) | 2012-11-28 | 2019-09-19 | Merck Sharp & Dohme Llc | Compositions and methods for treating cancer |
ES2707305T3 (es) | 2012-12-20 | 2019-04-03 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de HDM2 |
WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
EP3706742B1 (en) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5232929A (en) * | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
US5364943A (en) * | 1991-11-27 | 1994-11-15 | Pfizer Inc. | Preparation of substituted piperidines |
CZ293955B6 (cs) * | 1991-03-26 | 2004-08-18 | Pfizeráinc | Postup přípravy substituovaných piperidinů |
DE69213451T2 (de) * | 1991-06-20 | 1997-01-09 | Pfizer | Fluoralkoxybenzylaminoderivate stickstoffhaltiger heterocyclen |
US5340826A (en) * | 1993-02-04 | 1994-08-23 | Pfizer Inc. | Pharmaceutical agents for treatment of urinary incontinence |
US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
EP0653208A3 (en) * | 1993-11-17 | 1995-10-11 | Pfizer | Substance P antagonists for the treatment or prevention of sunburn. |
EP0655246A1 (en) * | 1993-11-30 | 1995-05-31 | Pfizer Inc. | Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria |
DE69623580T2 (de) * | 1995-12-21 | 2003-01-09 | Pfizer | 3-((5-Substituierte Benzyl)Amino)-2-Phenylpiperidine als Substance-P-Antagonisten |
US5990125A (en) | 1996-01-19 | 1999-11-23 | Pfizer Inc. | NK-1 receptor antagonists for the treatment of cancer |
-
1996
- 1996-06-04 TW TW085106675A patent/TW340842B/zh active
- 1996-06-10 AT AT96914375T patent/ATE208377T1/de not_active IP Right Cessation
- 1996-06-10 DK DK01108350T patent/DK1114817T3/da active
- 1996-06-10 JP JP09510015A patent/JP3084069B2/ja not_active Expired - Fee Related
- 1996-06-10 TN TNTNSN96107A patent/TNSN96107A1/fr unknown
- 1996-06-10 DE DE69631390T patent/DE69631390T2/de not_active Expired - Fee Related
- 1996-06-10 RO RO98-00334A patent/RO119299B1/ro unknown
- 1996-06-10 ES ES01108350T patent/ES2211684T3/es not_active Expired - Lifetime
- 1996-06-10 CA CA002227814A patent/CA2227814C/en not_active Expired - Fee Related
- 1996-06-10 ES ES96914375T patent/ES2163017T3/es not_active Expired - Lifetime
- 1996-06-10 SI SI9630374T patent/SI0861235T1/xx unknown
- 1996-06-10 PL PL96325332A patent/PL186773B1/pl not_active IP Right Cessation
- 1996-06-10 SI SI9630670T patent/SI1114817T1/xx unknown
- 1996-06-10 EP EP96914375A patent/EP0861235B1/en not_active Expired - Lifetime
- 1996-06-10 PT PT96914375T patent/PT861235E/pt unknown
- 1996-06-10 DK DK96914375T patent/DK0861235T3/da active
- 1996-06-10 AT AT01108350T patent/ATE258166T1/de not_active IP Right Cessation
- 1996-06-10 BR BR9609989A patent/BR9609989A/pt not_active Application Discontinuation
- 1996-06-10 CN CNB961965037A patent/CN1153764C/zh not_active Expired - Fee Related
- 1996-06-10 PT PT01108350T patent/PT1114817E/pt unknown
- 1996-06-10 WO PCT/IB1996/000572 patent/WO1997008144A1/en active IP Right Grant
- 1996-06-10 UA UA98020924A patent/UA48981C2/uk unknown
- 1996-06-10 RU RU98102959/04A patent/RU2152930C2/ru not_active IP Right Cessation
- 1996-06-10 AU AU57769/96A patent/AU702698B2/en not_active Ceased
- 1996-06-10 MX MX9801467A patent/MX9801467A/es active IP Right Grant
- 1996-06-10 CZ CZ0052198A patent/CZ297543B6/cs not_active IP Right Cessation
- 1996-06-10 HU HU9901159A patent/HU225480B1/hu not_active IP Right Cessation
- 1996-06-10 TR TR1998/00300T patent/TR199800300T1/xx unknown
- 1996-06-10 DE DE69616817T patent/DE69616817T2/de not_active Expired - Fee Related
- 1996-06-10 EP EP01108350A patent/EP1114817B1/en not_active Expired - Lifetime
- 1996-06-10 KR KR1019980701310A patent/KR100288673B1/ko not_active IP Right Cessation
- 1996-06-10 SK SK207-98A patent/SK282925B6/sk not_active IP Right Cessation
- 1996-06-10 NZ NZ308207A patent/NZ308207A/en unknown
- 1996-08-15 IL IL11907896A patent/IL119078A/xx not_active IP Right Cessation
- 1996-08-20 AR ARP960104045A patent/AR006305A1/es active IP Right Grant
- 1996-08-21 PE PE2001000276A patent/PE20010700A1/es not_active Application Discontinuation
- 1996-08-21 DZ DZ960130A patent/DZ2086A1/fr active
- 1996-08-21 PE PE1996000625A patent/PE1398A1/es not_active Application Discontinuation
- 1996-08-22 HR HR960386A patent/HRP960386B1/xx not_active IP Right Cessation
- 1996-08-23 MA MA24339A patent/MA23961A1/fr unknown
- 1996-08-23 YU YU47896A patent/YU49122B/sh unknown
- 1996-08-23 MY MYPI96003496A patent/MY114800A/en unknown
- 1996-08-24 AP APAP/P/1996/000850A patent/AP643A/en active
- 1996-08-26 CO CO96045248A patent/CO4480738A1/es unknown
-
1997
- 1997-12-30 IS IS4644A patent/IS1947B/is unknown
-
1998
- 1998-02-23 OA OA9800023A patent/OA10666A/en unknown
- 1998-02-23 NO NO19980751A patent/NO310720B1/no unknown
- 1998-02-27 BG BG102288A patent/BG64126B1/bg unknown
- 1998-12-30 HK HK98119203A patent/HK1014935A1/xx not_active IP Right Cessation
-
2000
- 2000-05-01 US US09/564,398 patent/US6506775B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2163017T3 (es) | Compuestos de bencilaminopiperidina sustituidos. | |
DE69232334D1 (de) | Substituierte 3-aminochinuclidine | |
ES2067466T5 (es) | Dispersante. | |
SE8102194L (sv) | Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna | |
ES2094843T3 (es) | Bencisotiazol- y bencisoxazol-3-carboxamidas, un procedimiento para su preparacion y su empleo como medicamentos antipsicoticos. | |
DK10488D0 (da) | Benzen-derivater med antiinflammatorisk virkning og fremgangsmaade til fremstilling deraf | |
LU90073I2 (fr) | Aceclofenac et ses sels et dérivés pharmaceutiquement acceptables (Air-tal) | |
ES2079590T3 (es) | Dihidrobenzofuran carboxamidas y procedimiento para su preparacion. | |
ES2059931T3 (es) | Procedimiento para el tratamiento de la hipertrofia e hiperplasia cardiaca asi como vascular. | |
ES2173435T3 (es) | Derivados condensados de 2,3-benzodiazepinas y su utilizacion como agentes inhibidores de receptores de ampa. | |
DK149590C (da) | Analogifremgangsmaade til fremstilling af 2-aryl-3,4-diaza-bicyclo(4,1,0)hepten-(2)-on-(5)-forbindelser | |
ES2152564T3 (es) | Procedimientos e intermedios para preparar 3-(1-piperazinil)-1,2-benzoisotiazol. | |
NO880405D0 (no) | Fremgangsmaate til fremstilling av 3-fenyl-7h-tiazolo-/3,2-b//1,2,4/-tiazine-7-oner. | |
DK0401093T3 (da) | Hidtil ukendte pyrrolidonderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler indeholdende disse | |
ES2176626T3 (es) | Compuestos de naftaleno, intermedios, formulaciones y procedimientos. | |
FI824155A0 (fi) | Foerfarande foer framstaellning av 3,7a-diazacyklohepta/j,k/fluoren | |
FI932650A (fi) | Foer skoetsel av B-cellers malignitet avsedda farmaceutiska blandningar | |
NO903585D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive 1,3-oksaziner. | |
DE59103080D1 (de) | 9-Amino-2-phenylbicyclo[3.3.1]nonane und 9-Amino-2-phenylbicyclo[3.3.1]-non-2-ene und diese enthaltende therapeutische Mittel. | |
DK0824100T3 (da) | Tricykliske piperidinylaminoforbindelser som substans P-antagonister | |
ES2037667T3 (es) | Procedimiento para la obtencion de indolinas. | |
JPS5416847A (en) | Biological denitrification method for night soil sewage | |
TH65060A3 (th) | การรักษาโรคของไวรัสในสุกร |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 861235 Country of ref document: ES |